Charity Atkins

Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1<i>H</i>-indol-5-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

Jeffrey M. Axten, Jesús R. Medina, Yanhong Feng et al. · Journal of Medicinal Chemistry · 2012 · 619 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

Charity Atkins, Qi Liu, Elisabeth A. Minthorn et al. · Cancer Research · 2013 · 429 citations

Medicine, Oncology, Pharmacology +14

Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development

Jeffrey M. Axten, Stuart P. Romeril, Arthur Y. L. Shu et al. · ACS Medicinal Chemistry Letters · 2013 · 230 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

Peter Sabbatini, Susan Korenchuk, Jason L. Rowand et al. · Molecular Cancer Therapeutics · 2009 · 98 citations · Full text

Medicine, Oncology, Pharmacology +13

Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase

Peter Sabbatini, Jason L. Rowand, Arthur Groy et al. · Clinical Cancer Research · 2009 · 80 citations · Full text

Medicine, Oncology, Pharmacology +16